Cambridge Healthtech Institute’s Second Annual
Peptide Therapeutics
Conquering Disease
Part of the 11th Annual PEGS: the essential protein engineering summit
May 6-7, 2015 | World Trade Center | Boston, Massachusetts

Preliminary Agenda


By 2018, the global Peptide Therapeutics market is expected to reach over $25 billion. This dramatic market increase is driven by both growing incidences of cardiovascular and metabolic diseases, and technological enhancements in peptide synthesis that include high-throughput approaches. Hybrid technology combining solid and liquid syntheses is also contributing to the growth of peptide therapeutics, as are novel modes of conjugation.

This meeting will explore the burgeoning world of Peptide Therapeutics and how peptides are being engineered to penetrate cancer tumors and conquer unmet medical needs. Improving peptide properties, such as stability and half-life, will also be discussed, along with innovating routes of administration. Case studies will be presented that illustrate the progress made in developing efficacious peptide therapeutics, while leaders in the field point the way to the future for these promising drugs.


Development of Bicyclic Peptides for Therapeutic Application

Christian Heinis, Ph.D., Professor, Therapeutic Peptides and Proteins, École Polytechnique Fédéral de Lausanne (EPFL)

High Affinity Bicyclic Peptides: Application to Payloads in Oncology

Christophe Bonny, Ph.D., CSO, Bicycle Therapeutics Limited

Lead Discovery and Optimization Strategies for Peptide Macrocycles

Abhijit Bhat, Ph.D., Vice President, Process Development, Redwood Bioscience, Inc.



Understanding the Mechanism of Physical Instability of Peptide Pharmaceuticals

Karolina Zapadka, Ph.D. Candidate, Formulation Group, MedImmune, LLC

Identifying Novel Drug Leads: Proteome-Wide Screening of Peptide Motifs that Inhibit Protein-Protein Interactions

Philip M. Kim, Ph.D., Associate Professor, The Donnelly Centre for Cellular and Biomolecular Research, Banting and Best Department of Medical Research, Molecular Genetics and Computer Science, University of Toronto



Cysteine Perfluoroarylation and Ultra Rapid Peptide Synthesis

Bradley L. Pentelute, Ph.D., Pfizer-Laubach Career Development Assistant Professor, Chemistry, Massachusetts Institute of Technology (MIT)

XTEN – A Biodegradable and Monodisperse PEG Alternative for Monthly Dosing of Peptides

Volker Schellenberger, Ph.D., President and CEO, Discovery, Amunix, Inc.



Role of Guanylate Cyclase Agonists in the Regulation of Gastrointestinal Function and Treatment of Gastrointestinal Diseases

Mark Currie, Ph.D., Senior Vice President, Chief Scientific Officer, and President of R&D, Ironwood Pharmaceuticals, Inc.

Orally Stable Peptides for Gastro-Intestinal Diseases
Dinesh V. Patel, Ph.D., President & CEO, Protagonist Therapeutics


Patient-Focused Peptide Delivery

Andrew Lewis, Ph.D., Director, Novel Drug Delivery Technologies, CMC&E Peptides, Ipsen

Lipid Conjugates for Peptide Drug Delivery

Jeffrey Wang, Ph.D., Associate Professor, Pharmaceutical Sciences, Western University of Health Sciences



For more details on the conference, please contact:
Mary Ruberry
Senior Conference Director
Cambridge Healthtech Institute
T: 781-972-5421

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471